Boston Trust Walden Corp Reduces Stock Position in Danaher Co. (NYSE:DHR)

by · The Cerbat Gem

Boston Trust Walden Corp cut its position in Danaher Co. (NYSE:DHR – Free Report) by 1.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 45,389 shares of the conglomerate’s stock after selling 679 shares during the period. Boston Trust Walden Corp’s holdings in Danaher were worth $12,619,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of DHR. Vanguard Group Inc. boosted its holdings in Danaher by 7.4% in the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after purchasing an additional 4,163,657 shares during the last quarter. Swedbank AB acquired a new position in shares of Danaher in the 1st quarter valued at about $676,545,000. TD Asset Management Inc boosted its stake in shares of Danaher by 99.0% in the second quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock worth $339,473,000 after buying an additional 675,952 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Danaher by 22.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock worth $761,475,000 after acquiring an additional 563,546 shares during the period. Finally, International Assets Investment Management LLC raised its position in Danaher by 40,196.5% during the third quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after acquiring an additional 428,897 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Down 1.1 %

Shares of NYSE:DHR opened at $245.39 on Friday. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The stock has a market cap of $181.76 billion, a P/E ratio of 41.59, a PEG ratio of 4.49 and a beta of 0.83. The business has a fifty day moving average of $269.52 and a two-hundred day moving average of $260.42. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR – Get Free Report) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the prior year, the firm posted $2.02 earnings per share. Danaher’s quarterly revenue was up 3.1% on a year-over-year basis. On average, research analysts expect that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were issued a dividend of $0.27 per share. The ex-dividend date was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. Danaher’s dividend payout ratio is currently 18.31%.

Analyst Upgrades and Downgrades

DHR has been the topic of several recent research reports. Leerink Partners upped their price objective on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Stifel Nicolaus lifted their price target on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research note on Wednesday. The Goldman Sachs Group increased their price objective on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Royal Bank of Canada cut their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research note on Wednesday. Finally, Barclays decreased their price target on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Seven research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $287.28.

Read Our Latest Analysis on Danaher

Insider Activity

In related news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Director Linda Filler sold 3,928 shares of the business’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.50, for a total value of $1,097,876.00. Following the sale, the director now owns 41,149 shares in the company, valued at approximately $11,501,145.50. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,059 shares of company stock valued at $8,400,897. 11.10% of the stock is currently owned by company insiders.

About Danaher

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Stories

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).